Business Wire

CRH Ventures Launches “Sustainable Building Materials” Accelerator to Scale Innovative Startups Shaping the Future of the Built World

21.10.2024 14:00:00 CEST | Business Wire | Press Release

Share

CRH Ventures, the venture capital unit of CRH, the leading building materials solutions business, today announced the launch of its latest accelerator, Sustainable Building Materials. Applications to the program are open until December 16.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241021822864/en/

Eduardo Gomez Mendoza, Head of CRH Ventures (Photo: Business Wire)

CRH is leading the transition to smarter, more sustainable construction and the Sustainable Building Materials accelerator will target promising Seed-, Series A- and Series B-stage companies in the construction technology (“contech”) and climate tech space with market-ready products. The program aims to identify innovative materials and applications to lower emissions, reduce waste and improve energy use - leveraging CRH’s extensive network and expertise to drive forward innovative and sustainable solutions for the built environment.

The accelerator will focus on exploring three key areas to enable more sustainable construction:

  • Sustainable binder solutions — companies enhancing the carbon performance and / or the circularity of traditional cement or concrete materials
  • New materials and applications companies developingnovel materials or new applications of existing materials to create non-traditional solutions for cement or concrete applications
  • CO2 mineralized materials companies utilizing CO2 in binders, aggregates, waste feedstocks or concrete to develop building materials or products that also offer carbon storage

This accelerator will identify startups poised to capitalize on the significant market opportunity decarbonization represents and support them as they develop and scale their operations. CRH Ventures will arrange one or more pilot programs for each shortlisted applicant, providing commercial users for products and facilitating technology refinement and engagement with selected partners in the construction space. Startups will also gain broader access to CRH’s network of 200+ operating companies, gaining insight from CRH experts and exploring synergies as they scale their technologies. Participants in the accelerator will also be eligible for potential investments from CRH Ventures at the conclusion of the pilot programs.

Eduardo Gomez, Head of CRH Ventures, said: “There’s an incredible opportunity to reduce construction-related emissions and enhance circularity through innovation. At CRH, we’re uniquely positioned to support the development of sustainable and innovative solutions and technologies to meet the changing needs of construction. In launching the Sustainable Building Materials accelerator, we plan to identify the most impactful innovations, and drive their commercial development through our network to support the construction industry to decarbonize and help CRH achieve its 2050 net-zero ambition.”

The accelerator will be accepting applicants via the CRH Ventures website through December 16. The selection process will continue throughout November and December, and will culminate in a live pitch day in early February 2025 for the most promising 10-12 startups.

Launched in 2022, CRH Ventures has established itself as a leader in construction innovation, with access to a $250-million venturing & innovation investment fund and a growing group of portfolio companies innovating across the construction value chain.

The Sustainable Building Materials program is CRH Ventures’ third accelerator. Earlier this year, it successfully launched the Roads of the Future accelerator to identify leading innovations with potential to impact the roads ecosystem and in 2023, it launched a Water Solutions accelerator focused on technologies that address a range of water management challenges.

About CRH Ventures

CRH Ventures is the venture capital unit of CRH, the leading provider of building materials solutions that build, connect and improve our world. With access to a $250M Venturing and Innovation Fund, CRH Ventures partners with and invests ambitiously and strategically in ConTech and ClimateTech start-ups across the entire construction value chain. For more information visit www.crhventures.com.

About CRH

CRH (NYSE: CRH, LSE: CRH) is the leading provider of building materials solutions that build, connect and improve our world. Employing approximately 78,500 people at approximately 3,390 operating locations in 28 countries, CRH has market leadership positions in both North America and Europe. As the essential partner for transportation and critical utility infrastructure projects, complex non-residential construction and outdoor living solutions, CRH’s unique offering of materials, products and value-added services helps to deliver a more resilient and sustainable built environment. The company is ranked among sector leaders by Environmental, Social and Governance (ESG) rating agencies. A Fortune 500 company, CRH’s shares are listed on the NYSE and the LSE. For more information visit www.crh.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241021822864/en/

Contacts

Media:
Jack Shaw
Antenna Group (for CRH Ventures)
CRH-Ventures@antennagroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye